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Introduction
Primary vaginal melanoma is an aggressive and rare
malignancy of the vagina, accounting for 0.3–1.3% of all
melanomas in women and 3% of all vaginal malignan-
cies [1,2]. They tend to occur in the sixth and seventh
decades of life, and present mostly on the distal or lower
one-third of the vagina, especially in the anterior and
anterior-lateral aspects of the vaginal wall. Although
several therapeutic modalities have been suggested, the
reported 5-year survival rate is dismal, ranging from 0%
to 25% [1,3,4]. Diagnosis is based on the presence of
melanin pigment within the tumor. However, additional
immunohistochemical examinations are required for
non-pigmented lesions to establish the diagnosis and
to differentiate these tumors from other cancers.
We report a case of amelanotic melanoma that
occurred on the unusual site of the upper one-third of
the vagina. Diagnosis was confirmed by the positive
staining for Melan-A, rather than S-100 or HMB-45.
Case Report
A 78-year-old, gravida 5, para 5, woman was brought
to our hospital with the chief complaint of postmeno-
pausal vaginal bleeding. Review of her past medical and
family history did not reveal any contributory factors.
Menopause occurred when she was in her forties, and
she had never used hormone replacement therapy.
Physical examination revealed two erythematous
lesions about 1 cm in size on the upper-third of the
vaginal wall (Figure 1). Biopsy of the lesion revealed
a high-grade sarcoma, although the possibility of
malignant melanoma was also suspected. Immuno-
histochemistry studies showed that the tumor cells were
positively stained with vimentin and CD-10, only focally
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positive for S-100, and negative for HMB-45 and
cytokeratin, indicating that the diagnosis of melanoma
was less likely (Figure 2). A series of examinations,
including pelvic computed tomography scan,
ultrasonography, chest X-ray, and blood chemistry,
showed no evidence of distant metastasis or tumor
invasion to adjacent organs.
The patient underwent wide local excision of the
vaginal tumor, total hysterectomy, and pelvic lymph
node sampling. The operative findings were a vaginal
tumor with no obvious extension to adjacent tissues.
The surgical margin was almost 1 cm free from tumor
involvement. The corpus uteri, adnexal and pelvic lymph
nodes were unremarkable. The postoperative course
was uneventful. Adjuvant therapy was suggested, but
the patient sought help from alternative medicine. No
evidence of tumor recurrence was detected 3 months
after surgery.
Histopathologic examination showed a high-grade
tumor with marked cellular atypia (Figure 3). The mitotic
counts were 2–3 per 10 high-powered fields. The tumor
cells involved the vaginal stroma, with depth of inva-
sion up to 2.5 mm. The corpus uteri, adnexal and pelvic
lymph nodes were free of tumor invasion. Immuno-
histochemistry studies showed that the tumor cells
stained with Melan-A (Figure 4), were only focally positive
for S-100 and CD-10, but negative for cytokeratin,
indicating its origin from melanocytes. The tumor cells
did not exhibit enhanced expression of CAM5.2, inhibin,
and CD31 (results not shown).
Discussion
Malignant melanoma of the vagina is a very rare tumor
entity that is mainly characterized by the presence of
melanin pigment within the tumor. However, less than
10% will lack pigmentation. Immunohistochemistry may
be required to provide additional diagnostic information
in these amelanotic tumors to establish the diagnosis
and to differentiate these tumors from other cancers
such as adenocarcinomas, small cell carcinomas, and
Figure 1. Gross appearance of vaginal malignant melanoma:
two erythematous nodular lesions (arrowheads) on the upper-
third of the vagina lateral to the uterine cervix.
Figure 2. Immunohistochemical studies revealed that the
vaginal tumor cells were: (A) focally positive for S-100;
(B) negative for HMB-45. (Original magnification = 400.)
Figure 3. Histopathology revealed a high-grade tumor with
marked cellular atypia (hematoxylin & eosin, original magnifi-
cation = 400).
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sarcomas [5]. S-100 is a calcium-binding protein that is
present in the nucleus and cytoplasm of melanocytes,
and it is one of the most sensitive markers for melanoma.
However, it is also positive in several other benign and
malignant tumors. Therefore, stains such as HMB-45
may be used concomitantly to confirm a diagnosis of
melanoma [6]. More recently, Melan-A has been
introduced as a marker for the diagnosis of melanoma,
especially when the results of S-100 or HMB-45 staining
are equivocal [7].
In clinical appearance, most patients with malignant
melanoma of the vagina are postmenopausal with a
range of complaints and symptoms. Most patients
present with nonspecific symptoms such as vaginal
bleeding, vaginal discharge and vaginal mass. Due to
the rarity of this disease, treatment modalities are
far from established. In most reports, treatment is
most commonly by surgery combined with or without
chemotherapy, cytokine or radiation. The role of com-
bined therapeutic modalities in improving survival
remains to be determined, and most of the patients
in the reported cases died or succumbed to recurrence
[8–14].
In summary, vaginal melanoma is an uncommon
disease with a poor prognosis. It may appear as a
pigmented or amelanotic lesion which needs to be
differentiated from other malignant tumors. Immuno-
histochemistry with S-100 and HMB-45 staining, or
with Melan-A as in this particular patient, may be
required to provide additional diagnostic information
to establish the diagnosis.
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Figure 4. Immunohistochemical studies of the vaginal tumor
cells showed strong staining with Melan-A (original magnifi-
cation = 400).
